ANN ARBOUR, Mich.–(BUSINESS WIRE)–ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer in enhanced ultrasound technologies, announces that management will present a company overview at the HC Wainwright BioConnect virtual conference to be held January 10-13, 2022. A webcast of the presentation will be available on-demand beginning January 10, 2022 at 7:00 a.m. EST on the Investors section of the ENDRA website.
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo-Acoustic Enhanced Ultrasound (TAEUS®), a breakthrough technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the patient’s point of care. TAEUS® is designed to work in concert with 400,000 cart-based ultrasound systems currently in use around the world. TAEUS® is initially focused on measuring fat in the liver as a way to assess and monitor non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), chronic liver conditions that affect over a billion people in the world, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS®, including visualization of tissue temperature during energy surgeries. For more information, please visit www.endrainc.com.